Cannabigerol, cannabinol and delta-8 are sold with big claims. This article checks each claim against the study behind it: was it shown in a lab dish, in a mouse, or in people?
Most consumer writing mixes up three kinds of evidence. A result in a laboratory dish, a result in animals and a result in people are different things. This article keeps them apart for every compound. It is for growers, shop staff and anyone who reads labels, seed listings or certificates of analysis, the lab reports that show what a sample contains.
Nothing here is a treatment recommendation. In Thailand, cannabis flower is a controlled herb. It can be sold only with a PT 33 (ภ.ท.33) prescription, for a maximum of 30 days. Advertising and online sale of flower are prohibited.
Part 1 explained what cannabinoids are, how the plant makes them, and what is known about tetrahydrocannabinol (THC) and cannabidiol (CBD).
This is Part 2. Part 1: The Cannabinoid Family: What Cannabinoids Are, How the Plant Makes Them, and the Evidence on Tetrahydrocannabinol and Cannabidiol (Part 1 of 2)
Terms Used in This Part
- Cannabinoid receptors: proteins on cells that react when a matching molecule attaches. Type 1 is dense in the brain and causes intoxication when THC switches it on. Type 2 sits mostly on immune cells.
- Agonist and antagonist: an agonist switches a receptor on. An antagonist blocks it.
- Acid forms: the living plant makes acid forms first, such as THCA and CBDA. Heat turns them into THC and CBD.
Cannabigerol (CBG)
The plant’s starting compound is cannabigerolic acid (CBGA), and cannabigerol (CBG) is its neutral form. The plant converts CBGA into the other cannabinoid acids as it grows. By harvest, most of it has been converted. This is why CBG is usually present only in trace amounts.
In 2010, Cascio and colleagues reported in the British Journal of Pharmacology how CBG acts. It is a potent agonist at the alpha-2 adrenoceptor, a receptor that responds to adrenaline and noradrenaline. It is an antagonist at 5-HT1A, a receptor for the brain chemical serotonin. It binds only weakly to cannabinoid receptors.
The antibacterial work was done in lab dishes and mice, not people
In 2020, Farha, Brown and colleagues published a study in the journal ACS Infectious Diseases. They tested cannabinoids against MRSA (methicillin-resistant Staphylococcus aureus). MRSA is a bacterium that resists several common antibiotics. This line of research is covered in more detail in cannabis as an antibacterial.
| What was tested | Result for CBG | What it means |
|---|---|---|
| Lab dish | One of seven compounds with a minimum inhibitory concentration of 2 micrograms per millilitre or less | The minimum inhibitory concentration is the lowest concentration that stops the bacteria growing |
| Mice with infection spread through the body | Worked about as well as vancomycin | Vancomycin is a standard hospital antibiotic for MRSA |
| Other bacteria | No activity on its own against Gram-negative bacteria | Gram-negative bacteria are a large group with an extra outer membrane |
So the evidence is a lab dish and a mouse. No human clinical trial of CBG as an antibacterial exists. No safe dose for taking it into the bloodstream has been established in people.
The only human trial
In 2024, Cuttler and colleagues published a human trial of CBG in the journal Scientific Reports. The trial was double-blind, which means neither the participants nor the researchers knew who received what. It was placebo-controlled and crossover, so each person took both CBG and a placebo, one week apart.
Thirty-four healthy adults who already used cannabis took a single 20 mg dose of hemp-derived CBG. After CBG, self-reported anxiety and stress were lower at some time points. Mood did not change.
The researchers stated the limits themselves. The group was small, healthy and made up of cannabis users, the dose was modest, and testing was done remotely. They also did not use multiple-comparison correction. This statistical adjustment reduces chance findings when many outcomes are measured.
Translator’s note: Some seed listings sell “high-CBG” strains. Most CBG has normally been converted by harvest. So before you buy seed in quantity, ask the seller for a lab report from a grown-out plant of that strain. Then grow a small test batch and have it tested, so you know what the strain gives in your own conditions.
What you can do: Do not repeat antibacterial or anti-anxiety claims for CBG as if they were proven. If you mention them, say exactly what they rest on: mice for the antibacterial claim, and one single-dose trial in 34 healthy people for anxiety.
Cannabinol (CBN)
The plant does not set out to make cannabinol (CBN). CBN forms when THC oxidises, which means it reacts with oxygen. Time, air, light and heat all speed this up. A sample with a high CBN level is therefore telling you about its age and how it was stored.
Sellers now market CBN almost entirely as a sleep aid. In 2021, a researcher named Corroon reviewed this claim in the journal Cannabis and Cannabinoid Research. The paper’s title was “Cannabinol and Sleep: Separating Fact from Fiction”. Corroon found:
- no clinical trials that used validated sleep questionnaires, meaning standard questionnaires tested to measure sleep reliably;
- no polysomnography studies, which are overnight sleep-lab recordings of brain waves, breathing and movement;
- that most human research is from the 1970s and 1980s, with small numbers of people;
- mixed evidence on whether CBN produces cannabis-like effects at all, with most studies showing that it does not.
Translator’s note: Thai storerooms often sit at 30–35 °C, and power cuts can stop the air conditioning. Heat speeds up the oxidation of THC into CBN, so stock kept in a hot room ages faster. See storing dried cannabis flower for containers and storage conditions.
What you can do: When you re-test a stored batch, compare its CBN and THC figures with the first lab report. If CBN has risen and THC has fallen, the THC is breaking down. Move the stock to an airtight container in a cooler, darker place, and use older stock first.
The Lesser-Studied Cannabinoids
Tetrahydrocannabivarin (THCV)
THCV has the same basic structure as THC but a shorter side chain, called a propyl chain. At low exposures it behaves almost the opposite way to THC.
In 2025, Haghdoost and colleagues published a perspective article on THCV in Cannabis and Cannabinoid Research. At most relevant doses, THCV is an antagonist at cannabinoid receptor type 1, so it blocks the receptor. It acts as an agonist only at higher doses. In humans, the subjective effects of a 10 mg dose taken by mouth could not be told apart from those of a placebo.
Cannabichromene (CBC)
In 2024, Sepulveda and colleagues reviewed CBC in the Journal of Pharmacology and Experimental Therapeutics. They describe it as an agonist at cannabinoid receptor type 2, binding about as strongly as THC does. Its action at type 1 is disputed. It is also a potent agonist at TRPA1, a channel nerves use to sense irritating substances.
The human data consist of two pharmacokinetic studies. These studies measure how the body absorbs and clears a compound, not whether it helps. The reviewers note that CBC products are sold with little evidence of safety or effectiveness.
Cannabidivarin (CBDV)
CBDV is related to CBD in the same way THCV is related to THC. It was studied as a possible anticonvulsant, meaning an anti-seizure drug.
It reached a Phase 2 trial in adults with focal seizures, which start in one area of the brain. A Phase 2 trial is a mid-stage test in patients. The trial missed its primary endpoint, the main result it was designed to show. Later work in autism spectrum disorder has not led to any approved use.
What you can do: If a product sells THCV, CBC or CBDV with a health claim, ask the seller which human study supports that claim. The reviews above found no human study showing a benefit for any of the three.
Delta-8 and the Semi-Synthetic Cannabinoids
What delta-8 is
Delta-8-tetrahydrocannabinol (delta-8-THC) occurs naturally in cannabis, but only in traces. In 2022, Kruger and Kruger described it in the Journal of Cannabis Research. It binds less strongly to cannabinoid receptor type 1 than ordinary delta-9-THC. A 1973 study found it about two-thirds as potent. So delta-8 is a weaker relative of THC, but it is still intoxicating.
How it is actually produced
The unusual part is the supply chain. The plant contains only traces of delta-8, so commercial delta-8 is not extracted. It is made from CBD. Acid is used to rearrange the CBD molecule into delta-8, a process chemists call acid-catalysed isomerisation.
The same route also produces hexahydrocannabinol (HHC). Both are semi-synthetic cannabinoids, which means they are made by chemically changing a compound taken from the plant.
In May 2022, the US Food and Drug Administration (FDA), the US medicines regulator, made three statements. Concentrated delta-8 is typically made from hemp-derived CBD. The FDA had received adverse event reports, including cases that needed hospital treatment. US poison control centres had received 2,362 exposure cases between January 2021 and February 2022.
The purity problem
The conversion is not clean. It leaves a mixture of compounds, and that mixture is the problem.
In 2022, Ray and colleagues analysed ten delta-8 products in the journal Molecules. They found impurities far beyond what the products’ certificates of analysis declared. Some of the compounds detected are not identified cannabinoids at all, so nobody knows their effects in humans.
Testing cited by Kruger and Kruger found 1.3 to 5.3% delta-9-THC in products sold as delta-8. It also found heavy metals. The delta-8 molecule itself is well understood. The products sold under its name are not.
An unsettled legal position
| Jurisdiction | Position as of writing |
|---|---|
| Thailand, flower | Cannabis flower is a controlled herb under the Notification of the Ministry of Public Health Re: Controlled Herbs (Cannabis), B.E. 2568, issued under the Thai Traditional Medicine Protection Act B.E. 2542. It has been in force since 26 June 2025. Sale is allowed only with a PT 33 prescription, for a maximum of 30 days. Advertising and online sale of flower are prohibited. The Ministerial Regulation on Controlled Herbs (No. 2) B.E. 2569, in force 30 April 2026, tightens the licence criteria for flower |
| Thailand, extracts | Extracts above 0.2% THC remain Category 5 narcotics under the Narcotics Code. Under the Ministerial Regulation on Cannabis or Hemp Extracts B.E. 2569 (in force 26 April 2026), extracts above 0.2% THC are licensed only to Thai juristic persons that are not “foreign” under the Foreign Business Act B.E. 2542, state agencies and the Thai Red Cross Society |
| Thailand, semi-synthetics | No Thai legal text naming delta-8 or HHC was found when this article was checked. The position is unsettled. An intoxicating extract above 0.2% in a system where flower is prescription-only is no place to assume permission. The draft Cannabis Control Act is not law yet: the Cabinet approved the draft on 22 September 2026 and sent it to the House. Until then, the rules rest on notifications and regulations that change often |
| European Union | The 2025 European Drug Report, the EU’s yearly report on drugs, records HHC in 27 European countries. It is controlled in at least 22 member states |
| United States | A federal law passed in November 2025 caps hemp products at 0.4 mg total THC per container. It also excludes cannabinoids synthesised outside the plant. A funding law signed on 2 September 2026 (H.R. 6500) moved the 0.4 mg cap and the other rules for naturally derived hemp THC to 11 December 2026. The exclusion of synthetic cannabinoids that the plant cannot produce still applies from 12 November 2026 |
The trend is the same everywhere. Regulators are closing the gap that let sellers argue a product was “not technically the controlled molecule”.
Translator’s note: Turning CBD into delta-8 or HHC is a chemical process. It is not clear how Thai licensing treats it. If it is treated as processing a controlled herb, doing it without a licence carries a penalty under Section 78 of the 1999 Act. The penalty is up to 1 year in prison, a fine of up to 20,000 baht, or both. Even where these products are legal, their contents are often unknown.
What you can do: Do not make, buy or stock delta-8 or HHC products in Thailand before you have a written answer from the licensing authority. If a customer brings one in, ask for its lab report. Look for delta-9-THC, unidentified compounds and heavy metals on that report.
The Entourage Effect
The entourage effect is the idea that cannabis compounds produce different effects together than each one does alone. As a hypothesis to test, it is reasonable. As a sales line, it claims far more than the evidence shows.
Simei and colleagues asked directly whether the effect exists. They published a narrative scoping review in Cannabis and Cannabinoid Research. A scoping review maps the research that exists on a question. They found three things:
- limited evidence that the effect is stable and predictable;
- preclinical results (from cell and animal studies) that disagree with each other;
- limited evidence for the effectiveness or safety of treatments built on the idea.
They urged industry, media and clinicians not to present the entourage effect as proven.
What has actually been shown is narrow. A 2021 paper in Scientific Reports found that several cannabis terpenes are cannabimimetic, which means they act like cannabinoids. Some of them selectively boosted cannabinoid activity. These were cell and rodent experiments.
Everything beyond that is extrapolation. Two examples are the claim that whole-plant products reliably work better in people, and the claim that a terpene profile produces a named effect. Sellers use the term because it turns the plant’s complexity into a selling point. It also justifies a higher price without any trial of that specific product.
What you can do: When a product is sold with an entourage-effect claim, ask whether that exact product was tested in people. If it was not, describe it only by its lab-measured contents.
Boiling Points, and Why Published Charts Disagree
Boiling-point figures on popular websites often give no source and no pressure. Turovsky and colleagues measured the values properly and published them in the Journal of Cannabis Research. They used two methods. Thermogravimetric analysis weighs a sample while heating it, to see when it evaporates. Differential scanning calorimetry measures how much heat the sample absorbs.
From these measurements, they estimated normal boiling points at atmospheric pressure:
- 245 ± 6 °C for delta-9-THC;
- 378 ± 4 °C for THCV.
The researchers explain that the widely quoted 157 °C figure for THC likely refers to a boiling point at reduced pressure; early work reported distilling THC at 157 °C under vacuum. Lower pressure lowers the boiling point. That is why a vacuum figure is far below a figure measured at normal air pressure. A boiling point given without its pressure or a source cannot be trusted.
What you can do: If a vaporiser temperature chart does not state the pressure and its source, do not rely on its figures. Note which chart you used whenever you post a vaporiser setting.
The Major Cannabinoids Compared
| Cannabinoid | Intoxicating | Main receptor action | Evidence in humans | Boiling point |
|---|---|---|---|---|
| Delta-9-THC | Yes | Partial agonist, types 1 and 2 | Strongest of the family: three symptom areas graded conclusive or substantial, plus documented harms | 245 ± 6 °C |
| CBD | No | Negative allosteric modulator at type 1 | Randomised evidence in three conditions with seizures; weak or absent elsewhere | Not documented |
| CBG | No | Alpha-2 adrenoceptor agonist, 5-HT1A antagonist | Lab and mouse antibacterial data; one small trial | Not documented |
| CBN | Not meaningfully | Weak binding at type 1 | Very thin; no modern controlled sleep trials found | Not documented |
| THCV | Not at low exposure | Type 1 antagonist at most relevant doses | A few small human studies | 378 ± 4 °C |
| CBC | No | Type 2 agonist; potent TRPA1 agonist | Two pharmacokinetic studies only | Not documented |
| CBDV | No | Close relative of CBD | Phase 2 seizure trial missed its main result | Not documented |
| THCA | No | Does not act on type 1 the way THC does | Chemistry and stability data only | Turns into THC when heated |
| CBDA | No | Precursor, different from CBD | Lab and animal data only | Turns into CBD when heated |
| Delta-8-THC | Yes | Type 1 agonist, weaker than delta-9 | Molecule well described; products sold under its name are not | Not documented |
The blank boiling points are deliberate. Figures circulate widely, but measurements you can trace to a source do not exist for these compounds.
The table shows a clear pattern. One compound, THC, has a real human evidence base and documented harms. One compound, CBD, has a narrow use reviewed by a regulator, with many marketing claims built around it. The evidence for the rest is thin.
One Habit to Take Away
Every time you meet a cannabinoid claim on a label, a seed listing or a social media post, check two things. First, was the result shown in a lab dish, in a mouse, or in people? Second, at what dose or exposure? Write both answers next to the claim before you repeat it.
Translator’s note: In Thailand, advertising cannabis flower is prohibited. Before you post any of these claims for a shop or farm, read the advertising and selling rules for cannabis.
If you have seen a cannabinoid described in a way the evidence does not support, post the claim in the replies below this topic and say where you saw it. Other members can check it against the studies listed here.
References (Part 2)
The original article gave its sources in the text only, without links. They are listed here as the original gives them.
- Cascio and colleagues. Pharmacology of cannabigerol at alpha-2 adrenoceptors and 5-HT1A receptors. British Journal of Pharmacology, 2010.
- Farha, Brown and colleagues. Antibacterial activity of cannabinoids against methicillin-resistant Staphylococcus aureus. ACS Infectious Diseases, 2020.
- Cuttler and colleagues. Double-blind, placebo-controlled crossover trial of 20 mg cannabigerol in 34 healthy adults. Scientific Reports, 2024.
- Corroon. “Cannabinol and Sleep: Separating Fact from Fiction”. Cannabis and Cannabinoid Research, 2021.
- Haghdoost and colleagues. “Tetrahydrocannabivarin is Not Tetrahydrocannabinol” (perspective article). Cannabis and Cannabinoid Research, 2025.
- Sepulveda and colleagues. Review of cannabichromene. Journal of Pharmacology and Experimental Therapeutics, 2024.
- Phase 2 trial of cannabidivarin in adults with focal seizures (no citation details given in the original).
- Kruger and Kruger. Review of delta-8-tetrahydrocannabinol. Journal of Cannabis Research, 2022. It cites a 1973 potency study and product testing for delta-9 and heavy metals.
- United States Food and Drug Administration. Statement on delta-8-tetrahydrocannabinol, May 2022.
- Ray and colleagues. Analysis of ten delta-8 products. Molecules, 2022.
- European Drug Report, 2025.
- United States federal law of November 2025 on hemp products (P.L. 119-37). Its rules for naturally derived hemp THC were moved to 11 December 2026 by H.R. 6500 (September 2026); the synthetic-cannabinoid exclusion applies from 12 November 2026.
- Simei and colleagues. “Does the ‘Entourage Effect’ in Cannabinoids Exist? A Narrative Scoping Review”. Cannabis and Cannabinoid Research, 2024.
- Paper on cannabimimetic terpenes. Scientific Reports, 2021.
- Turovsky and colleagues. Boiling points of cannabinoids by thermogravimetric analysis and differential scanning calorimetry. Journal of Cannabis Research, 2025.
This article is part of the Asiannabis Community educational series on medical cannabis. It is general information, not medical advice. Treatment decisions belong with a licensed practitioner. The content is for education within jurisdictions where medical cannabis is legally permitted.